Clinical Trial Update: Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS [Phase 2]

View source ↗

Summary

Phase 2 study of MD-1100 Acetate for gastrointestinal transit in irritable bowel syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• MD-1100 Acetate (tenapanor)

Snippet

Sponsor: Ironwood Pharmaceuticals, Inc. | Conditions: Irritable Bowel Syndrome | Phase 2 | Status: COMPLETED